Home / Conditions / Obesity (page 2)

Obesity

Obesity and Diabetes: Diabetes patients are considered obese when they have a Body Mass Index over 30. Such patients are at greater risk for a host of other problems cardiovascular disease, cancer, sleep apnea, and poor quality of life. Tremendous research is being done to control, manage, and reverse obesity in diabetics and the educated healthcare professional can help.

Maxed Out on Medications, Not Ready for Surgery: Is Metabolic Endoscopy the Missing Middle Ground?

Physician performing a metabolic endoscopy procedure showing endoscopic treatment of the stomach and digestive tract for type 2 diabetes management.

For many people living with type 2 diabetes, treatment eventually reaches a frustrating crossroads. Despite multiple medications, including GLP-1 receptor agonists, SGLT2 inhibitors, and insulin, glycemic targets may remain difficult to achieve. Meanwhile, bariatric surgery can produce major metabolic benefits, but its invasiveness limits acceptance for many patients. This treatment …

Read More »

Protecting Muscle While Treating Obesity: New Protein Targets for Older Adults on GLP-1s

Older adult performing strength training with protein-rich foods and muscle anatomy model, illustrating sarcopenia prevention during GLP-1 therapy and obesity treatment.

The rise of highly effective GLP-1 receptor agonists and dual incretin therapies has transformed obesity treatment. Medications such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are helping patients achieve levels of weight loss that were previously difficult to attain without bariatric surgery. However, as clinicians celebrate these advances, a …

Read More »

The Rise of “Double Diabetes”: Why More Adults With Type 1 Diabetes Are Developing Insulin Resistance

Adult with type 1 diabetes checking blood sugar levels alongside obesity and insulin resistance health concepts

More adults living with type 1 diabetes are now developing obesity, insulin resistance, hypertension, and metabolic complications once linked mainly to type 2 diabetes. This growing overlap, often called double diabetes, is becoming a major concern for clinicians and patients alike. While insulin therapy remains essential for type 1 diabetes …

Read More »

Beyond the FIB-4: Why Diabetes Care Is Becoming a Hepatology-Endocrinology Partnership

Doctor reviewing advanced liver imaging and metabolic health data during diabetes fatty liver disease screening consultation

Screening for fatty liver disease in patients with diabetes is no longer limited to identifying elevated liver enzymes or calculating a fibrosis score during an annual visit. Instead, clinicians are entering an era where diabetes care and hepatology increasingly overlap, especially as metabolic dysfunction-associated steatotic liver disease, or MASLD, becomes …

Read More »

When GLP-1 Therapy Plateaus: What Clinicians Should Do Next

Clinician reviewing patient progress during a GLP-1 plateau with metabolic trend chart on computer screen

Everything seems to be working perfectly until it suddenly isn’t. A patient is losing weight steadily, HbA1c levels are improving, and confidence is high during every follow-up visit. Then progress slows. The scale barely changes. Blood sugar readings stop improving. Patients start asking whether the medication has stopped working, while …

Read More »

GLP-1 Therapy and Muscle Loss: Are We Overlooking Sarcopenia Risk?

Medical illustration showing GLP-1 therapy, muscle mass preservation, weight loss, dumbbells, and body composition changes.

Losing 30 pounds may sound like an undeniable success story. However, what if part of that weight loss comes from muscle instead of fat? As more patients use GLP-1 medications such as semaglutide and tirzepatide, clinicians are starting to ask an important question: are these drugs quietly contributing to the …

Read More »

Fragmented Care in the GLP-1 Era: What Happens When Multiple Providers Prescribe the Same Therapy?

Patient navigating GLP-1 therapy while multiple healthcare providers coordinate diabetes and obesity treatment across telehealth and clinical settings.

A patient starts semaglutide through a telehealth platform, receives nutrition advice from a wellness clinic, and later visits a primary care physician for worsening gastrointestinal symptoms. None of the providers can see the full treatment picture. Situations like this are becoming increasingly common as GLP-1 medications move across multiple corners …

Read More »

Will Generic GLP-1 Drugs Change Diabetes Care? What Clinicians Should Expect Next

Generic GLP-1 drug injection pens and medication boxes representing the future of affordable diabetes care in a clinical setting.

The rapid rise of GLP-1 receptor agonists has transformed diabetes treatment and obesity management over the past decade. However, high prices and limited insurance coverage continue to restrict access for many patients. As patents evolve and global pharmaceutical markets shift, conversations about lower-cost GLP-1 therapies are gaining momentum. Clinicians are …

Read More »

Do GLP-1 Drugs Improve Osteoarthritis Outcomes? What New Trials Suggest About Pain and Mobility

Patient with knee osteoarthritis pain beside GLP-1 injection pens illustrating obesity-related joint treatment and mobility improvement

For many patients with obesity-related osteoarthritis, daily movement can feel like walking with a heavy backpack that never comes off. Joint pain limits exercise, reduced activity leads to more weight gain, and the cycle continues. However, new research is raising an important question: could GLP-1 therapies help break that cycle? …

Read More »

Oral GLP-1 Therapy in 2026: Will Easier Administration Change When We Start Treatment?

Oral GLP-1 therapy pills with glucose monitor and insulin pen for diabetes treatment

Could taking a pill instead of an injection change how early people begin treatment for type 2 diabetes or obesity? In 2026, these oral GLP-1 medications are gaining attention for their simplified dosing and improved convenience. As newer formulations reduce traditional barriers, clinicians are beginning to rethink when to initiate …

Read More »